<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="AntiviralAgents" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">AntiviralAgents</book-part-id>
      <title-group>
        <title>Antiviral Agents</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>6</month>
          <year>2018</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="AntiulcerAgents" document-type="chapter">Antiulcer Agents</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Apalutamide" document-type="chapter">Apalutamide</related-object>
    </book-part-meta>
    <body>
      <sec id="AntiviralAgents.OVERVIEW">
        <title>OVERVIEW</title>
        <p content-type="pubmed-excerpt">The antivirals are a large and diverse group of agents that are typically classified by the virus infections for which they are used, their chemical structure and their mode of action. Most antiviral agents have been developed in the last 20 to 25 years, many as a result of the major research efforts to develop therapies and means of prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Some of the agents developed to treat HIV infection, AIDS and its complications were found to also inhibit other viruses, and the novel approaches taken in development of antiretroviral therapy have been applied to develop therapies of other viral infections.</p>
        <p content-type="pubmed-excerpt"><bold>Antiretroviral Agents for HIV Infection</bold>. The antiretroviral agents include nucleoside analogues with reverse transcriptase activity (such as tenofovir, emtricitabine, lamivudine, abacavir, stavudine, didanosine, zidovudine), the nonnucleoside reverse transcriptase inhibitors (such as delavirdine, efavirenz, etravirine, nevirapine and rilpivirine), protease inhibitors (atazanavir, darunavir, indinavir, ritonavir, tipranavir and many others), and miscellaneous agents such as maraviroc that inhibits binding of the HIV virus its T cell receptor (CCR5 coreceptor antagonist), enfuvirtide that blocks the uptake of HIV into cells (fusion inhibitor), and integrase inhibitors (raltegravir, elvitegravir and dolutegravir) that block the integrase enzyme of HIV.</p>
        <p content-type="pubmed-excerpt"><bold>Hepatitis B Agents</bold>. The agents active against hepatitis B virus (HBV) include several nucleoside analogues that are also active against and used to treat HIV infection (tenofovir, emtricitabine, lamivudine), as well as agents that are poorly if at all active against HIV (adefovir, entecavir and telbivudine). Alpha interferon and peginterferon (its long acting pegylated form) are also active against hepatitis B, but are no longer commonly used for this indication.</p>
        <p><bold>Hepatitis C Agents</bold>. The agents active against hepatitis C virus (HCV) include interferon alfa (1992) and peginterferon (2000) which are used in combination with ribavirin, a nucleoside analogue that potentiates the effects of interferon against hepatitis C by unclearly defined mechanisms. Progress in treatment of hepatitis C began to accelerate in 2010 with the introduction of the first direct acting anti-HCV agents, two HCV-specific protease inhibitors: boceprevir and telaprevir. While combinations of these protease inhibitors with peginterferon and ribavirin yielded high response rates (60% to 75%), the regimens were poorly tolerated, expensive and prolonged (courses were typically for 48 weeks). Beginning in 2013, new direct acting anti-HCV agents with potent activity against different regions of the virus were introduced, which in combination obviated the need for interferon and yielded sustained response rates of greater than 90% with 12 to 24 weeks of treatment. The direct acting agents were directed against 3 components of HCV: HCV protease (NS3) inhibitors included simeprevir [2013], paritaprevir [2015], grazoprevir [2016] and glecaprevir [2017]); HCV RNA polymerase (NS5B) inhibitors included sofosbuvir [2013, a nucleoside analogue] and dasabuvir [2015, a non-nucleoside inhibitor]; and, HCV NS5A inhibitors included daclatasvir [2015], elbasvir [2016], lepidasvir [2014], ombitasvir [2015], velpatsvir [2016] and pibrentasvor [2017]. Combinations of 2 or 3 of these achieve sustained response rates of greater than 90%, with relatively short courses of therapy (8, 12 to 16 weeks) and without the need of interferon and its difficult and dose-limiiting side effects. These combinations are available under brand names such as Harvoni, Technive, Viekira Pak, Zepatier, Epclusa and Mavyret. Newer agents and different combination products are likely to be developed in the near future. Many of the earlier combinations are likely to be discontinued as newer regimens are more effective, better tolerated and active against all genotypes and in patients with renal disease, HIV infection or cirrhosis.</p>
        <p><bold>Herpes Virus Agents</bold>. The agents active against various herpes viruses (herpes simplex, varicella zoster, cytomegalovirus) include acyclovir and related acyclic nucleoside analogues such as valacyclovir, cidofovir, famciclovir, ganciclovir and valganciclovir, and other miscellaneous agents such as foscarnet.</p>
        <p><bold>Influenza Agents</bold>. The agents active against influenza A virus include amantadine and rimantadine which act on viral uncapping, and three neuraminidase inhibitors osteomavir (oral), zanamivir (by inhalation) and peramivir (intravenous). These agents are used during influenza outbreaks, generally for a brief period only, but are effective in prevention as well as amelioration of influenza infection.</p>
        <p>The following drug records are discussed individually:</p>
        <sec id="AntiviralAgents.Drugs_for_HIV_Infection">
          <title>Drugs for HIV Infection, in the Subclass Antiretroviral Agents</title>
          <list list-type="bullet">
            <list-item>
              <p>Fusion Inhibitors (HIV)</p>
              <list list-type="bullet">
                <list-item>
                  <p><related-object link-type="booklink" source-id="livertox" document-id="Enfuvirtide" document-type="chapter">Enfuvirtide</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Maraviroc" document-type="chapter">Maraviroc</related-object></p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Integrase Inhibitors (HIV)</p>
              <list list-type="bullet">
                <list-item>
                  <p><related-object link-type="booklink" source-id="livertox" document-id="Bictegravir" document-type="chapter">Bictegravir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Dolutegravir" document-type="chapter">Dolutegravir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Elvitegravir_Cobicis" document-type="chapter">Elvitegravir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Raltegravir" document-type="chapter">Raltegravir</related-object></p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>
                <related-object link-type="booklink" source-id="livertox" document-id="MonoclonalAntibodies" document-type="chapter">Monoclonal Antibodies</related-object>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>
                    <related-object link-type="booklink" source-id="livertox" document-id="Ibalizumab" document-type="chapter">Ibalizumab</related-object>
                  </p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Nonnucleoside Reverse Transcriptase Inhibitors (HIV)</p>
              <list list-type="bullet">
                <list-item>
                  <p><related-object link-type="booklink" source-id="livertox" document-id="Delavirdine" document-type="chapter">Delavirdine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Doravirine" document-type="chapter">Doravirine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Efavirenz" document-type="chapter">Efavirenz</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Etravirine" document-type="chapter">Etravirine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Nevirapine" document-type="chapter">Nevirapine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Rilpivirine" document-type="chapter">Rilpivirine</related-object></p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><related-object link-type="booklink" source-id="livertox" document-id="NucleosideAnalogues" document-type="chapter">Nucleoside Analogues</related-object> (HIV)</p>
            </list-item>
          </list>
          <list list-type="bullet">
            <list-item>
              <p><related-object link-type="booklink" source-id="livertox" document-id="Abacavir" document-type="chapter">Abacavir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Didanosine" document-type="chapter">Didanosine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Emtricitabine" document-type="chapter">Emtricitabine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Lamivudine" document-type="chapter">Lamivudine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Remdesivir" document-type="chapter">Remdesivir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Stavudine" document-type="chapter">Stavudine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Tenofovir" document-type="chapter">Tenofovir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Zidovudine" document-type="chapter">Zidovudine</related-object></p>
              <list list-type="bullet">
                <list-item>
                  <p><related-object link-type="booklink" source-id="livertox" document-id="HIVProteaseInhibitor" document-type="chapter">Protease Inhibitors</related-object> (HIV)</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><related-object link-type="booklink" source-id="livertox" document-id="AmprenavirFosampren" document-type="chapter">Amprenavir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Atazanavir" document-type="chapter">Atazanavir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Darunavir" document-type="chapter">Darunavir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="AmprenavirFosampren" document-type="chapter">Fosamprenavir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Indinavir" document-type="chapter">Indinavir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Lopinavir" document-type="chapter">Lopinavir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Nelfinavir" document-type="chapter">Nelfinavir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Ritonavir" document-type="chapter">Ritonavir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Saquinavir" document-type="chapter">Saquinavir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Tipranavir" document-type="chapter">Tipranavir</related-object></p>
            </list-item>
          </list>
        </sec>
        <sec id="AntiviralAgents.Drugs_for_Hepatitis_B">
          <title>Drugs for Hepatitis B</title>
          <list list-type="bullet">
            <list-item>
              <p><related-object link-type="booklink" source-id="livertox" document-id="Alpha_Peginterferon" document-type="chapter">Alpha Interferon</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Adefovir" document-type="chapter">Adefovir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Emtricitabine" document-type="chapter">Emtricitabine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Entecavir" document-type="chapter">Entecavir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Lamivudine" document-type="chapter">Lamivudine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Telbivudine" document-type="chapter">Telbivudine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Tenofovir" document-type="chapter">Tenofovir</related-object></p>
            </list-item>
          </list>
        </sec>
        <sec id="AntiviralAgents.Drugs_for_Hepatitis_C">
          <title>
            <related-object link-type="booklink" source-id="livertox" document-id="HepatitisCDrugs" document-type="chapter">Drugs for Hepatitis C</related-object>
          </title>
          <list list-type="bullet">
            <list-item>
              <p>Interferon Based Therapies</p>
              <list list-type="bullet">
                <list-item>
                  <p><related-object link-type="booklink" source-id="livertox" document-id="Alpha_Peginterferon" document-type="chapter">Alpha Interferon and Peginterferon</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Ribavirin" document-type="chapter">Ribavirin</related-object></p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>HCV NS5A Inhibitors</p>
              <list list-type="bullet">
                <list-item>
                  <p><related-object link-type="booklink" source-id="livertox" document-id="Daclatasvir" document-type="chapter">Daclatasvir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Zepatier" document-type="chapter">Elbasvir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Sofosbuvir" document-type="chapter">Ledipasvir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="ViekiraPak" document-type="chapter">Ombitasvir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Mavyret" document-type="chapter">Pibrentasvir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Sofosbuvir" document-type="chapter">Velpatasvir</related-object></p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>HCV NS5B (Polymerase) Inhibitors</p>
              <list list-type="bullet">
                <list-item>
                  <p><related-object link-type="booklink" source-id="livertox" document-id="ViekiraPak" document-type="chapter">Dasabuvir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Sofosbuvir" document-type="chapter">Sofosbuvir</related-object></p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>
                <related-object link-type="booklink" source-id="livertox" document-id="HCVProteaseInhibitor" document-type="chapter">HCV Protease Inhibitors</related-object>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p><related-object link-type="booklink" source-id="livertox" document-id="HCVProteaseInhibitor" document-type="chapter">Asunaprevir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Boceprevir" document-type="chapter">Boceprevir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Mavyret" document-type="chapter">Glecaprevir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Zepatier" document-type="chapter">Grazoprevir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="ViekiraPak" document-type="chapter">Paritaprevir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Simeprevir" document-type="chapter">Simeprevir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Telaprevir" document-type="chapter">Telaprevir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Sofosbuvir" document-type="chapter">Voxilaprevir</related-object></p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Combination Therapies</p>
              <list list-type="bullet">
                <list-item>
                  <p><related-object link-type="booklink" source-id="livertox" document-id="Sofosbuvir" document-type="chapter">Epclusa</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Sofosbuvir" document-type="chapter">Harvoni</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Mavyret" document-type="chapter">Mavyret</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="ViekiraPak" document-type="chapter">Technive</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="ViekiraPak" document-type="chapter">Viekira Pak</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Sofosbuvir" document-type="chapter">Vosevi</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Zepatier" document-type="chapter">Zepatier</related-object></p>
                </list-item>
              </list>
            </list-item>
          </list>
        </sec>
        <sec id="AntiviralAgents.Drugs_for_Herpes_Virus_I">
          <title>Drugs for Herpes Virus Infections (HSV, CMV, others)</title>
          <list list-type="bullet">
            <list-item>
              <p><related-object link-type="booklink" source-id="livertox" document-id="Acyclovir" document-type="chapter">Acyclovir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Cidofovir" document-type="chapter">Cidofovir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Famciclovir" document-type="chapter">Famciclovir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Foscarnet" document-type="chapter">Foscarnet</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="GanciclovirValganc" document-type="chapter">Ganciclovir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Letermovir" document-type="chapter">Letermovir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Valacyclovir" document-type="chapter">Valacyclovir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="GanciclovirValganc" document-type="chapter">Valganciclovir</related-object></p>
            </list-item>
          </list>
        </sec>
        <sec id="AntiviralAgents.Drugs_for_Influenza">
          <title>Drugs for Influenza</title>
          <list list-type="bullet">
            <list-item>
              <p><related-object link-type="booklink" source-id="livertox" document-id="Amantadine" document-type="chapter">Amantadine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Baloxavir" document-type="chapter">Baloxavir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Oseltamivir" document-type="chapter">Oseltamivir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Peramivir" document-type="chapter">Peramivir</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Rimantadine" document-type="chapter">Rimantadine</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Zanamivir" document-type="chapter">Zanamivir</related-object></p>
            </list-item>
          </list>
        </sec>
        <sec id="AntiviralAgents.Drugs_for_COVID19">
          <title>Drugs for COVID-19</title>
          <list list-type="bullet">
            <list-item>
              <p>
                <related-object link-type="booklink" source-id="livertox" document-id="Remdesivir" document-type="chapter">Remdesivir</related-object>
              </p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="AntiviralAgents.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 21 June 2018</p>
        <ref-list id="AntiviralAgents.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="AntiviralAgents.REF.n__ez.2013">
            <mixed-citation publication-type="book">N&#x000fa;&#x000f1;ez M. Hepatic toxicity of antiviral agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 505-18.<annotation><p><italic toggle="yes">(Review of hepatotoxicity of antiviral agents; mentions that risk of liver injury with different protease inhibitors is controversial, but that tipranavir, darunavir, lopinarivr and ritonavir are the leading causes in most case reports and reviews on the topic).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="AntiviralAgents.REF.flexner.2011">
            <mixed-citation publication-type="book">Flexner C. Antiretroviral agents and treatment of HIV infection. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1623-64.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="AntiviralAgents.REF3">
            <mixed-citation publication-type="web">
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://aidsinfo.nih.gov/guidelines">http://aidsinfo.nih.gov/guidelines</ext-link>
              <annotation>
                <p>
                  <italic toggle="yes">(Clinical guidelines on the use of antiretroviral agents in HIV-1 infected adults, adolescents and children).</italic>
                </p>
              </annotation>
            </mixed-citation>
          </ref>
          <ref id="AntiviralAgents.REF4">
            <mixed-citation publication-type="web">
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.hcvguidelines.org">www.hcvguidelines.org</ext-link>
              <annotation>
                <p>
                  <italic toggle="yes">(Clinical guidelines on the diagnosis, management and therapy of hepatitis C from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America, with regular updates).</italic>
                </p>
              </annotation>
            </mixed-citation>
          </ref>
          <ref id="AntiviralAgents.REF5">
            <element-citation publication-type="journal">
              <article-title>Antiviral drugs.</article-title>
              <source>Treat Guidel Med Lett</source>
              <year>2013</year>
              <volume>11</volume>
              <issue>127</issue>
              <fpage>19</fpage>
              <lpage>30</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of safety and efficacy of antiviral agents).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23459414</pub-id>
            </element-citation>
          </ref>
          <ref id="AntiviralAgents.REF6">
            <element-citation publication-type="journal">
              <article-title>Antiviral drugs for influenza 2013-2014.</article-title>
              <source>Med Lett Drugs Ther</source>
              <year>2014</year>
              <volume>56</volume>
              <issue>1434</issue>
              <fpage>6</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise summary of safety and efficacy of medications for influenza appropriate for the 2013-14 season mentions that adverse effects of oseltamivir include nausea, vomiting and headache; no mention of liver injury).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24457560</pub-id>
            </element-citation>
          </ref>
          <ref id="AntiviralAgents.REF.european_association_for_study_of_liver.2015.199">
            <element-citation publication-type="journal">
              <person-group>
                <collab>European Association for Study of Liver</collab>
              </person-group>
              <article-title>EASL Recommendations on Treatment of Hepatitis C 2015.</article-title>
              <source>J Hepatol</source>
              <year>2015</year>
              <volume>63</volume>
              <fpage>199</fpage>
              <lpage>236</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Guidelines for the antiviral therapy of chronic hepatitis C from the European liver clinical, academic and research society).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25911336</pub-id>
            </element-citation>
          </ref>
          <ref id="AntiviralAgents.REF.aasldidsa_hcv_guidance_panel.2015.932">
            <element-citation publication-type="journal">
              <person-group>
                <collab>AASLD/IDSA HCV Guidance Panel</collab>
              </person-group>
              <article-title>Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.</article-title>
              <source>Hepatology</source>
              <year>2015</year>
              <volume>62</volume>
              <fpage>932</fpage>
              <lpage>54</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Guidelines for the antiviral therapy of chronic hepatitis C from the US liver and infectious diseases research and academic societies).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">26111063</pub-id>
            </element-citation>
          </ref>
          <ref id="AntiviralAgents.REF9">
            <element-citation publication-type="journal">
              <article-title>Antiviral drugs for seasonal influenza 2016-2017.</article-title>
              <source>Med Lett Drugs Ther</source>
              <year>2017</year>
              <volume>59</volume>
              <issue>1511</issue>
              <fpage>1</fpage>
              <lpage>3</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise summary of safety and efficacy of medications for influenza appropriate for the 2016-17 season; discusses side effects of oseltamivir and zanamivir, but does not mention ALT elevations or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28026833</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
